Thomas Cartwright
Pulmonary Disease · Lebanon, INNPI 1740277466
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.2% of the total across 43 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by GSK at 33.6% of the total. Reporting peaked in 2021 at $400 and has fallen 87.0% since, to $52 in 2022. That places this record below the midpoint for pulmonary disease clinicians in IN, where the typical reported total is $2,226.
Across 43 payments — averaging $20.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$289
- Inspire Medical Systems, Inc.$117
- Mylan Specialty L.p.$53
- Regeneron Healthcare Solutions, Inc.$43
- AbbVie$33
- Pfizer$33
- plus $293 from 16 others
What the payments were for
- Speaking & faculty fees$132%
- Food & beverage$81995%
- Education$283%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 14 | $289 |
| Inspire Medical Systems, Inc. | 1 | $117 |
| Mylan Specialty L.p. | 3 | $53 |
| Regeneron Healthcare Solutions, Inc. | 2 | $43 |
| AbbVie | 2 | $33 |
| Pfizer | 2 | $33 |
| Boehringer Ingelheim | 2 | $30 |
| Amgen | 2 | $29 |
| Gilead | 2 | $29 |
| United Therapeutics Corporation | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| Avanir Pharmaceuticals, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Resmed Corp | 1 | $19 |
| AstraZeneca | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Fisher & Paykel Healthcare Inc | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
| Acorda Therapeutics, Inc | 1 | $13 |
| CSL Behring | 1 | $13 |
| Jazz Pharmaceuticals Inc. | 1 | $12 |
| Sanofi | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$860 in reported general payments places this provider in the 35th percentile of 258 pulmonary disease providers in Indiana.
Other pulmonary disease in Lebanon
- David MaresAnderson$1.3M
- David WilsonSeymour$689K
- Giovanni InfusinoCrown Point$526K
- Ajay DeshpandeTerre Haute$304K
- Faisal KhanGreenwood$207K
- Sandeep KukrejaGreenwood$206K
- Raja DevanathanHobart$193K
- Asaad JandaliMunster$161K
- Gaurav KumarPortage$102K
- Rajeev MehtaMuncie$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.